New drug combo targets HPV-Driven cancers in phase II trial

NCT ID NCT07684261

Not yet recruiting Disease control Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of two drugs—SYS6026 and Enlonstobart—in people with advanced solid tumors that have spread and are linked to HPV types 16 or 18. The study aims to see if the combination is safe and shows signs of shrinking tumors. Participants must be at least 18, have HPV 16/18-positive tumors, and be in relatively good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SYS6026 combined with Enlonstobart
What this could lead to: If successful, this combination therapy could offer a new treatment option for people with advanced solid tumors caused by HPV types 16 or 18.
What could go wrong: This is an early-phase trial with a small number of participants, so the treatment may not prove effective or may cause significant side effects. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED RECURRENT OR METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal carcinoma cervical cancer human papillomavirus-related squamous cell carcinoma laryngeal carcinoma lip and oral cavity carcinoma oropharyngeal carcinoma penile cancer vaginal cancer vulva cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

More trials for these conditions

Other studies related to the condition(s) this trial covers.